Mindray shareholders to meet in Hong Kong; Tyber Medical raises new funding;

@FierceMedDev: Becton Dickinson boost its quarterly dividend. Item | Follow @FierceMedDev

@MarkHFierce: J&J's $2.5B hip implant settlement offer is already beginning to generate some flack from patients. Story via NYT | Follow @MarkHFierce

> New Jersey's Tyber Medical closed a private placement equity round for an undisclosed amount. Plans call for using the money to accelerate marketing of its TyPEEK titanium plasma sprayed interbody fusion devices. Item

> Chinese medical device giant Mindray Medical ($MR) will hold its 2013 annual meeting at its Hong Kong offices on Dec. 17. Item

> Shareholders of Interlace Medical, which Hologic ($HOLX) snatched up in 2011, are suing the maker of women's health products for nearly $15 million in additional payments. Story

> Topera is touting results from a new independent multicenter clinical study showing that its 3-D mapping system helped improve long-term outcomes for atrial fibrillation patients. Item

> Bruker ($BRKR) won FDA clearance to market its new MALDI Biotyper CA System to identify gram-negative bacterial colonies cultured from human specimens. Item

Biotech News

@FierceBiotech: In our latest report, we feature the top women in the biotech industry. Report | Follow @FierceBiotech

@JohnCFierce: Sanofi might want to re-evaluate its cancer strategy about now. Iniparib and fedratinib both written off in '13. More | Follow @JohnCFierce

@DamianFierce: Pro-23andMe petition aims to protect "potentially life-saving diagnostic kits," thereby making the FDA's case. Petition | Follow @DamianFierce

@EmilyMFierce: Harvard study: 30% of all medical tests are probably unnecessary. More | Follow @EmilyMFierce

> Bayer's $2.4B bid to buy Algeta fits neatly with cancer drug strategy. Story

> Sanofi, Merrimack rack up third straight failure for lead cancer drug. Article

> BTG wins FDA OK for varicose vein treatment, projects $500M peak. Story

Pharma News

@FiercePharma: Monday's top story: Who leaked the scary Copaxone numbers? Teva intends to find out. Story | Follow @FiercePharma

@EricPFierce: Any who thinks women aren't controlling the destiny of biopharma would be wrong. Women in Biotech 2013 Report | Follow @EricPFierce

@CarlyHFierce: FDA withdraws restrictions on GSK diabetes drug Avandia - too little, too late? Story | Follow @CarlyHFierce

> Mylan, Biocon ready to roll out Herceptin biosimilar in India. Story

> FDA withdraws restrictions on GSK's Avandia. News

> Bayer bids $2.4B for Xofigo partner Algeta in drive for cancer growth. More

Pharma Manufacturing News

> JLL expects to buy more CMOs. Story

> Glaxo piles onto API expansion in Scotland. More

> PL Developments, Aaron combine expertise in OTC manufacturing. Article

> Ranbaxy ready to bail on vaccine manufacturing. More

> Bafna draws buyout interest for its European-approved manufacturing. News

Biotech Research News

> Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. News

> Biota halts preclinical antibiotics program as antimicrobial resistance grows. Report

> New targets for Parkinson's revealed in gene network. Story

> Antibiotics may weaken body's response to cancer therapies. Article

> New York Stem Cell Foundation, NIH partner to study rare diseases. Story

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.